M&A activity remains solid in life sciences.
Theme of this issue:
M&A activity remains solid in life sciences with a high number of announced deals, although deal values are not expected to hit the heady levels of 2014 and 2015. Oncology drives M&A in life sciences as key players seek to optimize their portfolios in anticipation of 10.9% CAGR growth to 2030. Chemical companies are increasingly focussing their M&A on application industries. Agrochemicals remains an M&A hotspot. The closing of the DowDuPont merger brought with it a spate of anti-trust divestments. US and China remain the most active countries in both sectors.
Browse directly through the publication
© 2020 KPMG AG Wirtschaftsprüfungsgesellschaft, a corporation under German law and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. For more detail about the structure of the KPMG global organization please visit https://home.kpmg/governance.